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CIDP

:   chronic inflammatory demyelinating polyneuropathy

EFNS/PNS

:   European Federation of Neurological Societies and the Peripheral Nerve Society

HRUS

:   high‐resolution ultrasound

Ig

:   immunoglobulin

IVIg

:   intravenous Ig

LMN

:   lower motor neuron

MMN

:   multifocal motor neuropathy

MRC

:   medical research council

NCS

:   nerve conduction study

NHL

:   non‐Hodgkin lymphoma

UMCU

:   University Medical Centre Utrecht

1. INTRODUCTION {#mus26629-sec-0005}
===============

The presence of persistent conduction block or other nerve conduction study (NCS) abnormalities suggestive of (multifocal) demyelination helps to distinguish chronic motor neuropathies that respond to immune modulating treatment, such as chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), from the more common neurodegenerative lower motor neuron (LMN) disorders. According to consensus diagnostic criteria, a combination of a compatible clinical phenotype and these NCS characteristics is sufficient for a diagnosis of "probable" or "definite" CIDP or MMN, which predicts a high probability of response to treatment.[1](#mus26629-bib-0001){ref-type="ref"}, [2](#mus26629-bib-0002){ref-type="ref"} Patients without electrodiagnostic features of demyelination are classified as having "possible" CIDP or MMN if results of additional ancillary investigations, such as brachial plexus MRI, albumino‐cytological dissociation in cerebrospinal fluid, or the titre of anti‐GM1 immunoglobulin (Ig) M antibodies (only for MMN), are abnormal.[3](#mus26629-bib-0003){ref-type="ref"} However, treatment response rates in such cases are relatively low. Other diagnostic strategies are required to limit the number of unsuccessful trials with intravenous immunoglobulin (IVIg).

We recently showed that high‐resolution ultrasound (HRUS) is a sensitive technique to identify patients with MMN and CIDP with characteristic NCS abnormalities.[4](#mus26629-bib-0004){ref-type="ref"} Only a few previous reports in single patients and a retrospective chart review have noted abnormal ultrasound findings in patients without these characteristic NCS findings.[5](#mus26629-bib-0005){ref-type="ref"}, [6](#mus26629-bib-0006){ref-type="ref"}, [7](#mus26629-bib-0007){ref-type="ref"}, [8](#mus26629-bib-0008){ref-type="ref"} Here we describe six patients suspected of an inflammatory neuropathy who lacked electrodiagnostic features of demyelination but had abnormal ultrasound findings. Response to treatment in the majority of these patients provides evidence that peripheral nerve ultrasound is a complementary diagnostic tool for evaluation of inflammatory neuropathies.

2. MATERIALS AND METHODS {#mus26629-sec-0006}
========================

2.1. Patients and routine ancillary investigations {#mus26629-sec-0007}
--------------------------------------------------

All patients in this study presented with a clinical phenotype of a subacute or chronic symmetric or asymmetric LMN syndrome compatible with a diagnosis of CIDP or MMN.[1](#mus26629-bib-0001){ref-type="ref"}, [2](#mus26629-bib-0002){ref-type="ref"} All were newly referred and treatment‐naive patients at the neuromuscular outpatient clinic at the University Medical Centre Utrecht (UMCU) who were seen between January 2014 and January 2016.[4](#mus26629-bib-0004){ref-type="ref"} They did not meet the inclusion criteria of the ongoing study to evaluate the diagnostic accuracy of HRUS in patients with inflammatory neuropathies[4](#mus26629-bib-0004){ref-type="ref"} because their NCS showed no electrodiagnostic features of demyelination.[2](#mus26629-bib-0002){ref-type="ref"}, [9](#mus26629-bib-0009){ref-type="ref"}, [10](#mus26629-bib-0010){ref-type="ref"}, [11](#mus26629-bib-0011){ref-type="ref"} They underwent extensive NCS according to a previously published standardized protocol after warming extremities in water at 37°C for 45 minutes[4](#mus26629-bib-0004){ref-type="ref"}, [9](#mus26629-bib-0009){ref-type="ref"} and routine ancillary investigations according to consensus diagnostic guidelines.[1](#mus26629-bib-0001){ref-type="ref"}, [2](#mus26629-bib-0002){ref-type="ref"} We used a previously published HRUS protocol of median nerves and brachial plexus trunks.[4](#mus26629-bib-0004){ref-type="ref"} The physiotherapist and clinical neurophysiologist (H.F.) were blinded to the HRUS results. The treating physicians (W.L.P., L.B.) were blinded to the details of HRUS evaluations and were not allowed to read the degree of (any) enlargement.

Five patients received IVIg treatment at a cumulative dose of 2 g/kg. We evaluated treatment effects assessed at intervals of 3 to 4 weeks after initial doses using the Medical Research Council (MRC) scale, and an experienced physiotherapist independently tested for muscle strength using dynamometry of hand, pinch‐ and key‐grip, myometry of large arm and leg muscles, and 10‐m walking tests.[12](#mus26629-bib-0012){ref-type="ref"}, [13](#mus26629-bib-0013){ref-type="ref"} Objective improvement was defined as an increase of ≥2 points on MRC scores (≥1 muscle group for hand and leg muscles, ≥1 muscle in upper arm), \>10% increment of dynamometry/myometry (≥1 muscle group), or \> 10% improvement in pinch/key‐grip or 10‐m walking test times.

2.2. Standard approval of protocols and consent {#mus26629-sec-0008}
-----------------------------------------------

The ethics committee of the UMC Utrecht approved the study protocol (14--328), and we obtained informed consent from all included participants.

3. RESULTS {#mus26629-sec-0009}
==========

Five patients had a subacute or chronic onset of asymmetric weakness of the arms or symmetric weakness of the legs, and one patient had progressive sensory ataxia. Patient characteristics are presented in Table [1](#mus26629-tbl-0001){ref-type="table"}, and results from ancillary investigations are presented in Table [2](#mus26629-tbl-0002){ref-type="table"} (see Table [S1](#mus26629-supitem-0002){ref-type="supplementary-material"}): chronic progressive asymmetric weakness compatible with MMN (patient 1), subacute/chronic progressive symmetric weakness of the legs and a single case of sensory ataxia fitting CIDP (patients 2--5 and patient 6, respectively) according to the European Federation of Neurological Societies and the Peripheral Nerve Society (EFNS/PNS) diagnostic consensus criteria. None of the patients met any of the electrodiagnostic criteria for demyelination (motor conduction velocity \> 2 SD below the lower limit of normal or other specified nerve conduction variables); most met only two of the required supportive criteria required for CIDP (patients 2--6), and one met only the current diagnostic criterion for possible MMN (patient 1).[1](#mus26629-bib-0001){ref-type="ref"}, [2](#mus26629-bib-0002){ref-type="ref"} Repeated NCS at a \> 6‐month interval revealed features of multifocal demyelination fulfilling the EFNS/PNS electrodiagnostic criteria[1](#mus26629-bib-0001){ref-type="ref"}, [2](#mus26629-bib-0002){ref-type="ref"} in patient 6 but not in the other patients (1‐5). Sonography results are presented in Table [3](#mus26629-tbl-0003){ref-type="table"} (see Figure [S1](#mus26629-supitem-0001){ref-type="supplementary-material"}). High‐resolution ultrasound was performed on the same day as the NCS in all but patient 6 (3‐week interval). One patient with progressive symmetric weakness and normal brachial plexus MRI results (patient 3) had lymphadenopathy according to HRUS and MRI. Non‐Hodgkin lymphoma (NHL) was eventually diagnosed in this patient, and hematological treatment resulted in clinical improvement of muscle strength. Consecutive courses of IVIg in the other five patients resulted in significant reduction of sensory ataxia (patient 6) and improvement of muscle strength (patients 1, 2, 4, and 5; Table [1](#mus26629-tbl-0001){ref-type="table"}, Table [S2](#mus26629-supitem-0003){ref-type="supplementary-material"}).

###### 

Patient characteristics

  Patient   Sex   Age, y    Disease duration, mo  First symptoms        Clinical findings                                                                                                                             Clinical phenotype   Improvement after treatment
  --------- ----- -------- ---------------------- --------------------- --------------------------------------------------------------------------------------------------------------------------------------------- -------------------- --------------------------------------------------------
  1         W     50                 34           Weakness right hand   Weakness and atrophy both hands                                                                                                               MMN                  Increased muscle strength both hands
  2         M     61                 3            Weakness both legs    Symmetric distal \> proximal weakness legs, low tendon reflexes, reduced vibration sense feet, postural tremor                                CIDP                 Increased muscle strength legs
  3         M     66                 6            Weakness both hands   Symmetric distal \> proximal weakness and atrophy arms, proximal weakness legs, reduced vibration sense feet, absent tendon reflexes          CIDP                 Increased muscle strength arms and legs
  4         M     75                 2            Paraesthesia feet     Symmetric distal \> proximal weakness legs, reduced vibration sense lower legs and hands, absent tendon reflexes, tremor and sensory ataxia   CIDP                 Increased muscle strength legs, reduced sensory ataxia
  5         M     58                 2            Paraesthesia feet     Symmetric proximal weakness arms and legs, absent tendon reflexes, postural tremor                                                            CIDP                 Increased muscle strength arms and legs
  6         M     75                 24           Paraesthesia feet     Symmetric hypoesthesia lower legs, absent tendon reflexes, sensory ataxia                                                                     CIDP                 Reduced sensory ataxia, gain in balance

Abbreviations: CIDP, chronic inflammatory demyelinating polyneuropathy; M, man; MMN, multifocal motor neuropathy; W, woman.

###### 

Summary routine ancillary investigations

  Patient   NCS(EFNS/PNS criteria are not fulfilled)                                                               MRI(brachial plexus)                                 CSF protein content, mg/dL  Supportive criteria EFNS/PNS[a](#mus26629-note-0005){ref-type="fn"}   Diagnostic criteria EFNS/PNS
  --------- ------------------------------------------------------------------------------------------------------ --------------------------------------------------- ---------------------------- --------------------------------------------------------------------- ------------------------------
  1         CMAP↓ median bilateral, right tibial + left fibular nerves                                             Normal                                                           37              1 (treatment)                                                         Not compatible
  2         CMAP ↓ of left and absent on right fibular nerve                                                       Normal                                                        **103**            2 (CSF, treatment)                                                    Not compatible
  3         SNAP↓ right median, both sural nerves                                                                  Normal[b](#mus26629-note-0006){ref-type="fn"}                   ...              1 (treatment)                                                         Not compatible
  4         DML↑ and SNAP↓ of right median nerve (CTS), CMAP↓ fibular and tibial nerves, SNAP↓ sural nerves        Normal                                                         **54**            2 (CSF, treatment)                                                    Not compatible
  5         Only chronodispersion F‐waves (median, ulnar, fibular + tibial)                                        Normal                                                         **52**            2 (CSF, treatment)                                                    Not compatible
  6         SNAP↓ right median, ulnar and radial, absent CMAP fibular and tibial nerves + SNAP both sural nerves   Enlargement + hyperintense T2‐signal right trunks                42              2 (MRI, treatment)                                                    Not compatible

Abbreviations: ..., data not available; CMAP, compound muscle action potential; CSF, cerebrospinal fluid (elevated protein content was defined as \>40 mg/dL, indicated in bold type); CTS, carpal tunnel syndrome; DML, distal motor latency; EFNS/PNS, European Federation of Neurological Societies and the Peripheral Nerve Society; NCS, nerve conduction study; SNAP, sensory nerve action potential.

Abnormal MRI brachial plexus (enlargement and/or T2 hyperintense signal (nerve)root(s), gadolinium contrast enhancement), increased CSF protein, objective improvement following treatment, and in the case of MMN, presence of anti‐GM1 antibodies.

Additionally diagnosed with non‐Hodgkin lymphoma.

###### 

Summary sonographic nerve size median nerves and brachial plexus

                                                                              Cross‐sectional area, mm^2^                                                                                  
  --- ---------------------------------------------------------------------- ----------------------------- ---------- ---------- ---------- ----- --------- --------- --------- ---------- ---------
      Normal value                                                                        \<9                 \<9        \<9        \<9      \<8     \<8       \<8       \<8       \<8        \<8
      Disease specific cutoff value[a](#mus26629-note-0007){ref-type="fn"}               \>10                 \>13       \>10       \>13     \>8     \>8       \>8       \>8       \>8        \>8
  1                                                                                       5.5                 7.9        7.0        6.8      3.3   **8.5**   **9.4**     5.4     **9.4**      8.3
  2                                                                                    **10.6**               11.0       10.2     **13.7**   5.3     7.0       4.9       6.5       6.1        5.5
  3                                                                                    **11.8**             **18.6**   **12.1**   **18.9**   6.0     5.7     **8.5**     5.2     **8.5**    **8.8**
  4                                                                                    **13.0**             **14.1**     9.6        10.7     6.1     3.4       4.8       5.9       4.9        5.4
  5                                                                                    **11.0**               11.9     **11.8**   **15.6**   7.3     5.0       5.2     **9.8**   **10.6**   **8.8**
  6                                                                                       9.5               **14.2**     10.4     **13.8**   7.3     5.4       4.1     **9.7**     7.5        6.2

Sonographic enlargement of nerve size (median nerve at forearm and upper arm and brachial plexus any trunk) compatible with chronic inflammatory neuropathy indicated in boldface type.

4. DISCUSSION {#mus26629-sec-0010}
=============

Enlargement of nerves of the upper arm and brachial plexus detected with HRUS is a hallmark for inflammatory neuropathies, including CIDP and MMN.[4](#mus26629-bib-0004){ref-type="ref"} The results from this case series provide evidence that HRUS may also be helpful in identifying the more elusive patients in which electrodiagnostic features of demyelination are absent. Only a small minority of patients (\<15%) with a clinical phenotype that may suggest MMN, but without the characteristic conduction block in combination with abnormal ancillary investigations, respond to IVIg treatment.[14](#mus26629-bib-0014){ref-type="ref"} High‐resolution ultrasound, therefore, may represent not only a useful complementary diagnostic tool but may also eventually help to reduce the cost of IVIg trials that are the consequence of the current guidelines for the treatment of patients with LMN syndromes.

The six patients had the same pattern of sonographic nerve enlargement of proximal segments of median nerve and brachial plexus that we observed in our larger series of untreated patients with CIDP or MMN.[4](#mus26629-bib-0004){ref-type="ref"} This supports the hypothesis that the six patients presented here had CIDP/MMN and not another as yet unspecified treatment‐responsive LMN syndrome. However, the patient with nerve enlargement and NHL is a clear illustration of the requirement for clinical caution when HRUS and NCS diverge. Therefore, electrodiagnostic and HRUS results should always be viewed in the clinical context because treatment decisions should not be based on a single abnormal test result such as nerve size or only one enlarged nerve site.

We do not think that we failed to identify electrophysiological abnormalities because we used and even repeated an extensive NCS protocol that did not yield characteristics of demyelination in our patients. Our findings are in agreement with previous studies that noted sonographic enlargement in nerves without apparent demyelinating nerve conduction abnormalities.[15](#mus26629-bib-0015){ref-type="ref"}, [16](#mus26629-bib-0016){ref-type="ref"}, [17](#mus26629-bib-0017){ref-type="ref"}, [18](#mus26629-bib-0018){ref-type="ref"} The complementary role of HRUS and NCS in the diagnostic evaluation of chronic inflammatory neuropathies mirrors that of focal neuropathies.[19](#mus26629-bib-0019){ref-type="ref"}, [20](#mus26629-bib-0020){ref-type="ref"}, [21](#mus26629-bib-0021){ref-type="ref"}, [22](#mus26629-bib-0022){ref-type="ref"}, [23](#mus26629-bib-0023){ref-type="ref"} In addition, HRUS may also have prognostic value in chronic inflammatory neuropathies.[24](#mus26629-bib-0024){ref-type="ref"}, [25](#mus26629-bib-0025){ref-type="ref"}, [26](#mus26629-bib-0026){ref-type="ref"}, [27](#mus26629-bib-0027){ref-type="ref"}, [28](#mus26629-bib-0028){ref-type="ref"} Magnetic resonance imaging results of the brachial plexus were abnormal in only one patient, which may suggest that the larger field of view of HRUS offers a diagnostic advantage compared to MRI. The sonographic protocol presented here takes less than 15 minutes and is time and cost efficient. Taken together, nerve ultrasound is warranted in patients in whom CIDP and MMN are suspected, both for helping to minimize overtreatment and, particularly, for early identification of treatable patients.
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